Moderna, Merck personalized mRNA cancer vaccine cuts melanoma recurrence 42% in Phase 3
The first late-stage win for a personalized mRNA cancer vaccine sparked both broad coverage and a Wall Street sell-off in vaccine makers.
STAT · +13 outlets
Roche's KRAS drug divarasib shows strong lung cancer data at ESMO
The divarasib study was among the most impressive datasets presented at this year's ESMO cancer meeting.
STAT · +3 outlets
Bristol Myers Squibb reports patient death in autoimmune CAR-T trial
The patient died 44 days after receiving zola-cel, prompting BMS to explain the case and seek to resume the program.
Biopharmadive · +13 outlets
Merck, Kelun ADC cuts death risk by one-third in advanced endometrial cancer
The Phase 3 result adds to Merck's oncology pipeline as it deepens its ADC portfolio.
STAT · +8 outlets
Incyte touts lasting pancreatic cancer responses, sees itself neck and neck with RevMed
Incyte's KRAS G12D targeted drug produced durable tumor responses in combination with chemotherapy in certain patients.
STAT · +1 outlets
Bon Secours Mercy Health strikes $5.7 billion deal for surgery center chain
The acquisition would make the Catholic nonprofit one of the largest operators of outpatient surgery centers.
STAT · +1 outlets
GSK sees return to cancer start to pay off, with sixth oncology drug nearing approval
GSK re-entered oncology a decade ago after exiting the field and is now positioning a broad cancer portfolio.
STAT · +5 outlets
ESMO roundup: cancer vaccine debate, Roche KRAS progress, Amgen 'unprecedented' data
Melanoma vaccine data drew scientific praise but a Wall Street selloff, while a lung drug earned a standing ovation.
Biopharmadive · +1 outlets
BioNTech, DualityBio say ADC showed 'modest' benefit in HER2-low breast cancer
The companies said the treatment has limited impact in an area where AstraZeneca and Daiichi Sankyo's Enhertu leads.
Biopharmadive · +10 outlets
Corxel, an obesity drugmaker, to go public via SPAC with $300 million financing
The deal adds another GLP-1 and amylin-focused company to the public markets.
Biopharmadive · +7 outlets
HHS relaxes security and transparency rules for hospital EHR software
The Trump administration removed several privacy, security and transparency requirements for EHR vendors under interoperability rules.
STAT · +4 outlets
House lawmaker probes PBMs over 'punitive' audits of independent pharmacies
The investigation examines whether the three largest pharmacy benefit managers targeted independent pharmacies with retaliatory audits.
STAT · +2 outlets
Bristol Myers touts '5 out of 5' positive Phase 3 trials for bispecific ADC iza-bren
The company presented the results at ESMO as it advances the bispecific antibody-drug conjugate.
Fierce Pharma · +1 outlets
J&J exec calls RIPTAC readout 'best data we've ever seen' for a prostate cancer drug
The early-stage RIPTAC results were presented at ESMO and drew an unusually strong claim from the company.
Fierce Biotech · +1 outlets
Genmab to test drug candidate with unnamed US biotech partner
The Danish antibody developer is expanding its pipeline through a new collaboration.
MedWatch
Sumitomo's enzomenib gets FDA breakthrough designation for rare acute leukemia
The designation covers relapsed or refractory KMT2A-rearranged acute leukemia.
BioSpace · +2 outlets
ABL Bio gastric cancer bispecific shows 79% tumor shrinkage in Phase 1b
The company said FDA Phase 3 design talks for the bispecific antibody are complete.
BigGo Finance
Opus Genetics' presbyopia eye drop wins FDA approval
The approval gives the company a commercial product and a runway projected into 2029.
TradingView · +1 outlets